FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Related Articles
Anumana to Showcase AI-Driven Cardiovascular Solutions at AHA and NAPCRG 2024
Company to highlight how its ECG-AI™ algorithms enable earlier cardiovascular disease detectionNovember 14, 2024
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
BioSpace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer Inc. for Anumana to develop an artificial intelligence electrocardiogram…December 15, 2022
Mayo Clinic launches 2 new companies to use patient data and AI to advance early disease detection
FIERCE Healthcare: Mayo Clinic has launched a new initiative to collect and analyze patient data from remote monitoring devices and diagnostic tools and to use artificial intelligence to accelerate diagnoses…April 13, 2021
New Project Trains AI on a Hard-to-Diagnose Cardiac Issue
Health Leaders: A start-up from the Mayo Clinic orbit is partnering with Pfizer to develop an AI-enhanced ECG that can detect cardiac amyloidosis, a progressive disease that's difficult to diagnose…December 16, 2022